Elanco Strengthens Board of Directors with Addition of Stacey Ma

Core Insights - Elanco Animal Health has appointed Dr. Stacey Ma to its Board of Directors, effective immediately, enhancing the company's expertise in biopharmaceutical development and manufacturing [1][2]. Company Overview - Elanco Animal Health is a global leader in animal health, dedicated to innovating and delivering products and services to prevent and treat diseases in farm animals and pets, with nearly 70 years of heritage in the industry [6]. Leadership and Expertise - Dr. Ma brings extensive global leadership experience in biopharmaceutical development and manufacturing, currently serving as Executive Vice President at Gilead Sciences, where she oversees product and portfolio strategy, technical development, supply chain, quality, CMC regulatory, and manufacturing operations [3][5]. - Dr. Ma has held leadership positions at Sana Biotechnology and Genentech/Roche, contributing significantly to product development and technical innovation [3][4]. Strategic Contributions - Dr. Ma's expertise in Chemistry, Manufacturing and Controls (CMC) strategy and technical operations is expected to be valuable as Elanco transitions significant products from research to manufacturing scale-up [5]. - Her role will also support Elanco's Innovation, Portfolio and Productivity (IPP) strategy, aimed at developing a consistent flow of high-impact innovations in the company's next-generation pipeline [5].